Hrt Financial LP Celyad Oncology Sa Transaction History

Hrt Financial LP

  • $18.1 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
SELL
$1.55 - $2.32 $5,443 - $8,147
-3,512 Reduced 9.54%
33,288 $57,000
Q1 2022

May 16, 2022
SELL
$1.72 - $4.08 $2,244 - $5,324
-1,305 Reduced 3.42%
36,800 $88,000
Q4 2021

Feb 14, 2022
BUY
$3.56 - $5.0 $135,653 - $190,525
38,105 New
38,105 $139,000

About Celyad Oncology SA

CYAD Quotes by TradingView
  • Ticker CYAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,594,000
  • Market Cap $11.7M
  • Description
  • Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cance...
More about CYAD
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email